Pharmaceuticals company Boehringer Ingelheim expects to invest more than $50 million in its Xochimilco plant in Mexico, with the aim of increasing and improving production by its diabetes segment in the next three years. The company also plans to invest $25 million in its veterinary products plant in Guadalajara, with an expansion to be completed in 2021.